《大行報告》瑞銀:比亞迪(01211.HK)季績預告大致符預期
瑞銀發表報告指出,比亞迪(01211.HK)季績預告大致符預期,公司估計去年純利介乎290億至310億元人民幣,按年增長74%至86%,意味著去年第四季純利按季跌7%至27%,至76.33億至96.33億元人民幣,但仍按年增長4%至32%,業績上限符合市場預期98.72億元人民幣水平,但下限則低過預期。
該行預期,比亞迪今年將推出超過10款新車型、新技術包括第五代DM混動技術、純電e平台4.0,以及改善先進駕駛輔助系統(ADAS),有助公司維持國內超過30%的市佔率。維持對其「買入」評級,目標價360元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.